CYCLE GROUP HOLDINGS LIMITED

Figures converted to GBP from USD at 0.748 per USD (Frankfurter spot rate) — hover any figure for the original. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +31.8%

  £75,705,315 → £99,792,928

• Cash

  +156.9%

  £21,745,533 → £55,873,514

• Net assets

  +117.4%

  £19,366,824 → £42,109,591

• Employees

  +14.4%

  97 → 111

• Operating profit

  +535.9%

  £4,825,447 → £30,686,253

• Profit before tax

  +673.7%

  £3,799,806 → £29,399,716

• Wages

  +34.2%

  £10,471,705 → £14,050,235

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Group is a profitable and cash generative pharmaceutical company, delivering revenue growth of 32% to $133,493k, Operating Profit of $41,049k and had net cash at 31 December 2024 of $58,544k. Management has prepared a cash flow forecast for a twelve-month period following the approval of the financial statements, showing continued growth of the business, which will enable the Group to continue as a going concern.”

Group structure

1. CYCLE GROUP HOLDINGS LIMITED · parent
   1. Cycle Pharmaceuticals Ltd 100% · United Kingdom · Development of pharmaceutical products
   2. Cycle Pharmaceuticals Incorporated 100% · USA · Promotion of pharmaceutical products and patient support
   3. Varsity Pharmaceuticals Limited 100% · United Kingdom · Inactive
   4. Cycle Pharmaceuticals (Europe) Limited 100% · Ireland · Dormant

Significant events

• “On 10 January 2025, the Group purchased 100% of the shares of Banner Life Sciences LLC for upfront consideration of $51.6m, funded from cash on hand.”
• “On 18 March 2025, a new branded generic product VENXXIVA was launched in the US market.”
• “On 28 March 2025, the Group signed a Revolving Credit Facility, providing the Group with $100m of borrowing capacity.”
• “On 3 April 2025, the Group repaid all outstanding amounts due under the Deutsche Bank loan ($14.5m) and repurchased for cancellation all remaining warrants for $5m.”
• “On 18 April 2025, the Group signed a commercialisation agreement with Handa Pharma to commercialise PHYRAGO in the US, an approved treatment for rare forms of leukaemia.”
• “On 9 May 2025, the Group signed a commercialisation agreement with Lupin Inc to launch a branded generic form of glycerol phenylbutyrate.”
• “On 10 June 2025 the FDA approved HARLIKU (nitisinone) for the treatment of Alkaptonuria (AKU) a rare, inherited, metabolic disorder.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

19

last 12 months

Capital events

12

last 24 months

Officers appointed

2

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.